Esperion Therapeutics, Inc. (ESPR)
3.14
-0.01
(-0.32%)
USD |
NASDAQ |
Jun 09, 16:00
3.14
0.00 (0.00%)
After-Hours: 20:00
Esperion Therapeutics SG&A Expense (Quarterly) : 43.12M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 2.70B |
| Nektar Therapeutics | 13.44M |
| Corcept Therapeutics, Inc. | 145.36M |
| Eli Lilly & Co. | 2.934B |
| Indivior Pharmaceuticals, Inc. | 124.00M |